Connect with us

Health & Fitness

Tildrakizumab for Psoriasis Shows Durable Efficacy Over 5 Years

The full 5-year results of a study of tildrakizumab for psoriasis show a high rate of sustained disease control coupled with a favorable safety profile during more than 5400 patient-years of follow-up. Medscape Medical News

Published

on

Tildrakizumab for Psoriasis Shows Durable Efficacy Over 5 Years